Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10030005 | GENENTECH INC | Inhibitors of RET |
Nov, 2036
(12 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11273160 | GENENTECH INC | RET inhibitor for use in treating cancer having a RET alteration |
Apr, 2039
(14 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Sep 04, 2025 |
Orphan Drug Exclusivity(ODE-341) | Dec 01, 2027 |
Orphan Drug Exclusivity(ODE-340) | Dec 01, 2027 |
Orphan Drug Exclusivity(ODE-318) | Sep 04, 2027 |
NCE-1 date: 04 September, 2024
Market Authorisation Date: 04 September, 2020
Treatment: Treatment of adult patients with metastatic rearranged during transfection (ret) fusion-positive non-small cell lung cancer (nsclc) as detected by an fda approved test; Treatment of adult and pediatri...
Dosage: CAPSULE;ORAL